Statement Re: Merger of Subsidiaries
The Directors of
Freyherr Pharma d.o.o. is the universal legal successor to Freyherr d.o.o. and has assumed all its rights and obligations and acquired all its tangible and intangible assets. The business and services provided by the Slovenian companies remain unchanged and Freyherr Pharma d.o.o. becomes a direct 100% subsidiary of
"We're delighted that we've now completed the merger of these two companies. This integration will facilitate the improvement of our processes and streamline our internal communications and reporting lines. It should also simplify the application processes for further GMP certificates and other licensing and regulatory approvals."
The directors of the issuer accept responsibility for the contents of this announcement
For further information please contact:
|
|
Tomaž Frelih No.1
|
00 386 (41) 444 845 |
CITY & MERCHANT LIMITED Corporate Advisor Level 17 Dashwood House EC2M 1QS
|
0207 101 7676 |
HELFORD CAPITAL PARTNERS LLP Investor Relations SW1Y 6JE
|
020 7839 5081 |
Note to Editors:
Freyherr Pharma d.o.o. is the pharmaceutical arm of the Group and holds an EU GMP certificate. It operates from a certified production facility, manufactures CBD products for the Group and produces white label CBD products for customers in various EU countries. Its quality assurance department specializes in EU pharmaceutical quality systems, and particularly those relating to cannabis specifically. An important strength of Freyherr Pharma is also research and development department which has expertise in the cultivation, processing, formulation and legal and regulatory compliance of cannabis-based products. Freyherr Pharma has also invested in cannabis production facilities in other jurisdictions.
Patron d.o.o. is the dispenser production arm which has been operating since 2015. It develops, produces and markets products suitable for dosing concentrates and extracts. The company also offers analytical services for the determination of the cannabinoid content (CBD, THC and 11 other cannabinoids) of dried plant material, extracts, concentrates or finished products.
This information is provided by RNS, the news service of the